New developments and clinical transition of hyaluronic acid-based nanotherapeutics for treatment of cancer: reversing multidrug resistance, tumour-specific targetability and improved anticancer efficacy
Autor: | Humna Hasan, Muhammad Hassan Safdar, Zahid Hussain, Mohammed A.S. Abourehab, Sajal Afzal, Hnin Ei Thu |
---|---|
Rok vydání: | 2017 |
Předmět: |
0301 basic medicine
Biomedical Engineering Cancer therapy Pharmaceutical Science Medicine (miscellaneous) Antineoplastic Agents 02 engineering and technology Pharmacology Metastasis 03 medical and health sciences chemistry.chemical_compound Drug Delivery Systems Neoplasms Hyaluronic acid Medicine Animals Humans Hyaluronic Acid biology business.industry CD44 Cancer General Medicine 021001 nanoscience & nanotechnology medicine.disease Drug Resistance Multiple Multiple drug resistance 030104 developmental biology chemistry Drug Resistance Neoplasm Cancer cell biology.protein Cancer research Nanocarriers 0210 nano-technology business Biotechnology |
Zdroj: | Artificial cells, nanomedicine, and biotechnology. 46(8) |
ISSN: | 2169-141X |
Popis: | This review aims to overview and critically analyses recent developments in achieving tumour-specific delivery of anticancer agents, maximizing anticancer efficacy, and mitigating tumour progression and off-target effects. Stemming from critical needs to develop target-specific delivery vehicles in cancer therapy, various hyaluronic acid (HA)-conjugated nanomedicines have been fabricated owing to their biocompatibility, safety, tumour-specific targetability of drugs and genes, and proficient interaction with cluster-determinant-44 (CD44) receptors over-expressed on the surface of tumour cells. HA-based conjugation or surface modulation of anticancer drugs encapsulated nanocarriers have shown promising efficacy against the various types of carcinomas of liver, breast, colorectal, pancreatic, lung, skin, ovarian, cervical, head and neck and gastric. The success of this emerging platform is assessed in achieving the rapid internalization of anticancer payloads into the tumour cells, impeding cancer cells division and proliferation, induction of cancer-specific apoptosis and prevention of metastasis (tumour progression). This review extends detailed insight into the engineering of HA-based nanomedicines, characterization, utilization for the diagnosis or treatment of CD44 over-expressing cancer subtypes and emphasizing the transition of nanomedicines to clinical cancer therapy. |
Databáze: | OpenAIRE |
Externí odkaz: |